Spanish
CDV was recognized with the “Animal Health Awards” after a year marked by milestones in new products, strategic alliances, investments and sustainable growth.
CDV CDV laboratory was distinguished in London with the prestigious award for Best World Animal Health Company, in the tenth edition of the “Animal Health Awards 2024”. CDV was previously awarded as leading animal health company for LatAm in 2019 and 2023.
Unlike previous editions, this year’s award was not region-based but on a worldwide scale instead. This achievement reaffirms the company’s commitment to animal wellbeing and its comprehensive approach to sustainability and prevention, aligned with the “One Health” philosophy.
“This award not only validates our work, but it’s a reflection of the entire CDV team’s commitment. It drives us to continue innovating and enhancing our solutions to improve animals’ quality of life, increase herds’ productivity and contribute to global well-being” , highlighted Juan Roo, General Manager at CDV Laboratories.
CDV has completed the civil works of the most advanced plant in the veterinary industry, with an investment of US$80MM. This modern facility, which will be operational soon, will comply with the most demanding international regulations, with a three-fold production capacity increase.
Note that an exclusive plant for the production of vaccines against brucellosis was simultaneously inaugurated, in tandem with a research and development subsidiary in the United States, focused on advanced biotechnology, covering technologies such as messenger RNA and recombinant proteins.
The company continues to accelerate its global expansion, consolidating its presence in Latin America, Asia, Africa and Europe, and reaching more than 200 new approved registrations last year. “This sustained growth drives the planning of a fourth plant, aimed at meeting the growing demand for quality products worldwide,” added Roo.
Thanks to its strategic alliance with Genneia, 80% of energy resources comes from renewable sources, making it the first Argentine veterinary laboratory to achieve this significant accomplishment.
In the field of innovation, the laboratory is developing vaccines across several species, including Equine Encephalomyelitis and others for pigs and pets, achieving significant breakthroughs in each of these lines.
On the occasion of its 40th anniversary in 2025, the company is expecting 26% growth, while it aims to self-position among the top 20 veterinary laboratories worldwide in the coming years.
The recent achievement reinforces leadership, highlighting its contribution to livestock productivity and a safe and sustainable food system. “We are proud to maintain this recognition in Argentina, since it reflects our human capital talent, professional excellence, and the development of cutting-edge technology,” concluded CDV executive.
Further to this award, the company emphatically dedicated it to all their staff, clients, veterinarians, producers, institutions and anyone working to improve production.
About CDV:
CDV is a leading Argentine laboratory specialized in the production of vaccines for the prevention of diseases that affect cattle and sheep herds, with 40 years of experience in Argentina. Their prevention-oriented line of products and services is the most complete line on the market, including vaccines against viruses and bacteria, vaccination for foot-and-mouth disease, reagents and diagnostic service. Innovating in the production of aquaculture vaccines since 2002. CDV laboratory was distinguished as the “Best company in the Veterinary Sector in Latin America” by the British magazine Animal Health in 2019 and 2023. CDV exports their products to more than 20 countries.
It owns two modern vaccine production plants, and a third one is under construction, all of them located in the Pilar Industrial Park, province of Buenos Aires:
Plant 1: since 2003 we have been producing vaccines for the prevention of reproductive, respiratory, clostridial diseases, keratoconjunctivitis, enteric neonatal complex and preventive of important zoonotic diseases such as Brucellosis, Rabies, Carbuncle and Leptospirosis. Aso a diagnostic reagents producer for the detection of Tuberculosis and Brucellosis as well as vaccines to prevent diseases in birds and salmonids. The same premises host a Diagnostic Laboratory of the SENASA network. Annual total production capacity of 150MM doses, out of which 85 million doses go to bovine vaccines and the rest to salmonids and birds.
Plant 2: exclusively allocated to FMD (Aftosa) vaccine production since 2018. This Plant includes state-of-the-art equipment and a high degree of system automation to ensure compliance with the most demanding quality and biosafety standards worldwide. With a productive capacity of over 60MM doses of foot-and-mouth vaccine.
Plant 3: currently under construction and estimated to be operational during the first half of 2025. The productive capacity of Plant 1 will be enhanced and products for animal health and disease prevention in new species will be produced: vaccines for pets, companion animals and pigs. The total projected production capacity will reach – together with the production of plant 1- 280MM doses, out of which 190MM go to bovine vaccines. Follow the work in progress on livestreaming: https://cdv.com.ar/live/